Clinical trials · Philadelphia, PA
Prostate cancer clinical trials in Philadelphia
We’re tracking 64 recruiting prostate cancer studies with a site in or near Philadelphia — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Philadelphia
- NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07219303Recruiting
Adaptive radiation therapy for intermediate- or high-risk prostate cancer
This trial tests a type of radiation that adjusts to changes in your prostate during treatment. It aims to improve accuracy and reduce side effects for men with intermediate- or high-risk prostate cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06533644RecruitingPhase 2
SYNC-T therapy study for advanced prostate cancer
This trial tests a new treatment called SYNC-T Therapy (SV-102) for men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The therapy is given directly into a tumor to help your immune system fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06064149Recruiting
Heart risk study for men on hormone therapy for prostate cancer
This study looks at heart health in men with prostate cancer who are taking or will take hormone therapy (ADT) for at least 6 months. It aims to learn more about cardiovascular risks and how to manage them.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06095089RecruitingPhase 1
Study of two drugs for advanced prostate cancer
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06991556RecruitingPhase 2
Testing JSB462 plus abiraterone for advanced prostate cancer
This trial tests a new drug called JSB462 combined with abiraterone in men with prostate cancer that has spread to other parts of the body and is still responding to hormone therapy. The goal is to see if this combination works better than current treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05804318Recruiting
Adaptive daily radiation for low- and intermediate-risk prostate cancer
This trial tests a radiation plan that is adjusted every day using your own scans to better target prostate cancer. It may help reduce side effects while still treating the cancer effectively in men with lower- or intermediate-risk disease.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Philadelphia, PennsylvaniaAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after abiraterone
This trial tests whether a drug called talazoparib, alone or combined with enzalutamide, can help people with a certain type of advanced prostate cancer that has stopped responding to abiraterone. It is for those who have a specific genetic change (HRR mutation) in their tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07111507RecruitingPhase 2
Tarlatamab for advanced prostate cancer
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new drug to standard care for prostate cancer
This trial tests a new study drug (AAA817) against the usual treatments for men with a certain type of advanced prostate cancer that has spread and is no longer responding to a targeted radiation therapy (177Lu-PSMA). The goal is to see if the new drug can help control the disease longer.
Philadelphia, PennsylvaniaAges 18–100 - NCT07493512RecruitingPhase 1
Study of xaluritamig for metastatic prostate cancer
This trial tests a new drug called xaluritamig for men with metastatic prostate cancer that is resistant to hormone therapy. It is designed for those who have already tried certain hormone pills and one type of chemotherapy, and aims to see if the drug can shrink tumors or slow cancer growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Philadelphia, PennsylvaniaAges 21 years+ - NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Philadelphia, PennsylvaniaAges Any age - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Philadelphia, PennsylvaniaAges 12 years+
Hear when a new Prostate cancer trial opens near Philadelphia, PA
We’ll email you when one opens near Philadelphia, PA — at most once a week, no account needed, unsubscribe anytime.
Prostate cancer trials in other cities
Where these studies are running near Philadelphia
Institutions with a site for the recruiting prostate cancer studies listed above.
- Thomas Jefferson University Hospital · 11 studies
- Fox Chase Cancer Center · 8 studies
- University of Pennsylvania · 4 studies
- Asplundh Cancer Pavilion · 2 studies
- Christiana Care Health System-Christiana Hospital · 2 studies
- Helen F Graham Cancer Center · 2 studies
- Medical Oncology Hematology Consultants PA · 2 studies
- MidLantic Urology · 2 studies
What taking part in a prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting prostate cancer studies in Pennsylvania.
Common questions
- Are there prostate cancer clinical trials near Philadelphia?
- Yes. We're currently tracking 64 recruiting prostate cancer studies with a site near Philadelphia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer study near Philadelphia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Philadelphia to take part?
- Not necessarily. These studies have a site near Philadelphia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer studies open near Philadelphia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.